Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
Transfus Med Rev. 2019 Jan;33(1):7-11. doi: 10.1016/j.tmrv.2018.07.001. Epub 2018 Jul 12.
Anemia is a frequently diagnosed condition that may be a symptom of or complication of many illnesses affecting patients of all demographics. Anemia can lead to both worsened clinical outcomes and reduced quality of life. Patient-reported outcome measures (PROMs) are methodological tools used to capture the impact of disease on patient well-being. Use of PROMs in medical research is becoming more common as it is increasingly recognized that disease outcomes of interest to researchers and clinicians are not always consistent with patients' greatest concerns related to their diseases. We conducted a scoping review to characterize the studies that have evaluated patient-centered outcomes using PROMs in patients undergoing treatment for anemia. We conducted a search of Medline (Ovid), EMBASE (Ovid), PsychINFO, and CINAHL databases for studies published until January 2017 that investigated an intervention to treat anemia in any patient population and used at least 1 PROM to evaluate patient-centered outcomes. A descriptive synthesis was performed to characterize the PROMs used and to evaluate the quality of patient-centered outcome (PCO) reporting. Of the 3224 studies identified in the initial search, 130 met all eligibility criteria. We found that the population most frequently studied was oncology patients (46.2% of studies). The therapy for anemia evaluated in the most studies was erythropoietin-stimulating agents (77.7% of studies). The most commonly used PROM was the Functional Assessment of Cancer Therapy/Functional Assessment of Chronic Illness Therapy tool (46.9%), and the majority of studies used only 1 PROM tool (53.1%). We found significant variability in the quality of PCO reporting across all included studies. Improved methodologic rigor in the assessment of PCOs in anemia management is needed in future studies.
贫血是一种常见的疾病,可能是许多影响所有人群的疾病的症状或并发症。贫血可导致临床结局恶化和生活质量降低。患者报告的结局测量(PROM)是用于捕获疾病对患者健康影响的方法学工具。随着越来越多的人认识到,研究人员和临床医生感兴趣的疾病结果并不总是与患者对其疾病的最大关注点一致,因此在医学研究中越来越多地使用 PROM。我们进行了一项范围综述,以描述评估接受贫血治疗的患者使用 PROM 评估以患者为中心的结局的研究。我们在 Medline(Ovid)、EMBASE(Ovid)、PsychINFO 和 CINAHL 数据库中进行了检索,检索截至 2017 年 1 月的研究,这些研究调查了治疗任何患者人群贫血的干预措施,并使用至少 1 个 PROM 评估以患者为中心的结局。进行描述性综合以描述使用的 PROM,并评估以患者为中心的结局报告的质量。在最初的搜索中确定了 3224 项研究,其中 130 项符合所有入选标准。我们发现,研究最多的人群是肿瘤患者(46.2%的研究)。评估的贫血治疗方法在大多数研究中是促红细胞生成素刺激剂(77.7%的研究)。最常用的 PROM 是癌症治疗功能评估/慢性疾病治疗功能评估工具(46.9%),大多数研究仅使用 1 个 PROM 工具(53.1%)。我们发现,所有纳入研究的 PCO 报告质量存在显著差异。在未来的研究中,需要在贫血管理中评估 PCO 方面提高方法学严谨性。